In this study, we used datasets from TCGA and CGGA to study the role of ZNF503-AS2 in glioma and its relationship with prognosis, molecular subtype, immune microenvironment, inflammatory response, and immune checkpoint blockade (ICB) treatment. This evidence concerns the gene ZNF503 and central nervous system cancer.